169. Menkes disease
6 clinical trials,   6 drugs   (DrugBank: 3 drugs),   0 gene,   0 pathway

Searched query = "Menkes disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04337684
(ClinicalTrials.gov)
December 1, 20191/4/2020Long Term Follow-up on Menkes Disease PatientsLong Term Follow-Up and Collection of Historical Control Data on Menkes Disease PatientsMenkes DiseaseDrug: Long Term Follow-UpCyprium Therapeutics, Inc.NULLEnrolling by invitationN/AN/AAll50United States
2NCT04074512
(ClinicalTrials.gov)
August 31, 201927/8/2019Copper Histidinate Treatment for Menkes DiseaseCopper Histidinate Treatment for Menkes DiseaseMenkes DiseaseDrug: Copper HistidinateCyprium Therapeutics, Inc.NULLAvailableN/A6 YearsAllNULL
3JPRN-UMIN000030626
2014/11/2828/12/2017Investigation on the effectiveness of histidine copper treatment of Menkes disease patients Menkes diseaseWeekly,subcutaneous injection of histidine copper (750microgram once) is performed three times per week.It is continued every week until the end of the research during the research period.Hamamatsu University School of MedicineNULLComplete: follow-up completeNot applicableNot applicableMale and Female2Not selectedJapan
4JPRN-UMIN000005259
2011/03/0318/03/2011Clinical trial of histidine-copper and diethyldithiocarbamate combination therapy for patients with Menkes disease Menkes diseasegive a dose of copper-histidine and diethyldithiocarbamateKobe Unniversitu Graduate School of MedicineNULLComplete: follow-up completeNot applicableNot applicableMale and Female2Not selectedJapan
5NCT00811785
(ClinicalTrials.gov)
February 27, 200918/12/2008Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper DeficiencyMolecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper DeficiencyMenkes Disease;Occipital Horn Syndrome;Unexplained Copper DeficiencyDrug: Copper HistidineCyprium Therapeutics, Inc.Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);National Center for Complementary and Integrative Health (NCCIH)CompletedN/A80 YearsAll93Phase 3United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00001262
(ClinicalTrials.gov)
June 19903/11/1999Copper Histidine Therapy for Menkes DiseasesEarly Copper Histidine Therapy in Menkes DiseaseKinky Hair SyndromeDrug: Copper HistidineEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NULLCompletedN/AN/AAll60Phase 1;Phase 2United States